Contributions
Abstract: EP1519
Type: ePoster
Abstract Category: Therapy - disease modifying - Risk management for disease modifying treatments
Background: Delayed-type hypersensitivity to glatiramer acetate is rare, A few cases of urticarial vasculitis (UV) induced by glatiramer acetate (GA) have been described.
Objective: We report a new case of UV induced by GA 9 months after starting the treatment.
Case report: A 37-year-old female patient, monitored in our neurology clinic upon multiple sclerosis diagnosis. She had started GA treatment 9 months previously. She presented at emergency complaining of itching and rash on the body. Dermatological, neurological and systemic examination was normal, and showed urticaria-like plaques on the body, face and extremities. Laboratory analyses (including leukocites, C-reactive Protein, inmunoglobulines and complement) did not shown anormality. Histopathological examination of the material taken from the lesion on the patient"s right leg by punch biopsy demonstrated interstitial and perivascular infiltration of all the dermis by neutrophils, with evident leukocytoclastia, dilated and congested vessels with partial inflammatory infiltrate and hematic extravasation. The patient was clinically and histopathologically diagnosed with UV, stopped GA and 1 mg/kg per day of systemic corticosteroid and 20 mg per day of Bilastine treatment was started. All the lesions abated on the third day of treatment. Patch testing with undiluted glatiramer acetate was also performed althought the result were negative.
Conclusion: Urticarial vasculitis (UV) is a disease characterized clinically by urticarial skin lesions and histologically by leukocytoclastic vasculitis caused by immunocomplex accumulation in post-capillary venules. It is known that delayed-type hypersensitivity to GA is rare. This is the second case of UV induced by GA reported.
Disclosure: Authors declare no conflict of interest
Abstract: EP1519
Type: ePoster
Abstract Category: Therapy - disease modifying - Risk management for disease modifying treatments
Background: Delayed-type hypersensitivity to glatiramer acetate is rare, A few cases of urticarial vasculitis (UV) induced by glatiramer acetate (GA) have been described.
Objective: We report a new case of UV induced by GA 9 months after starting the treatment.
Case report: A 37-year-old female patient, monitored in our neurology clinic upon multiple sclerosis diagnosis. She had started GA treatment 9 months previously. She presented at emergency complaining of itching and rash on the body. Dermatological, neurological and systemic examination was normal, and showed urticaria-like plaques on the body, face and extremities. Laboratory analyses (including leukocites, C-reactive Protein, inmunoglobulines and complement) did not shown anormality. Histopathological examination of the material taken from the lesion on the patient"s right leg by punch biopsy demonstrated interstitial and perivascular infiltration of all the dermis by neutrophils, with evident leukocytoclastia, dilated and congested vessels with partial inflammatory infiltrate and hematic extravasation. The patient was clinically and histopathologically diagnosed with UV, stopped GA and 1 mg/kg per day of systemic corticosteroid and 20 mg per day of Bilastine treatment was started. All the lesions abated on the third day of treatment. Patch testing with undiluted glatiramer acetate was also performed althought the result were negative.
Conclusion: Urticarial vasculitis (UV) is a disease characterized clinically by urticarial skin lesions and histologically by leukocytoclastic vasculitis caused by immunocomplex accumulation in post-capillary venules. It is known that delayed-type hypersensitivity to GA is rare. This is the second case of UV induced by GA reported.
Disclosure: Authors declare no conflict of interest